Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer

Zeleke, T. Z., Pan, Q., Chiuzan, C., Onishi, M., Li, Y., Tan, H., Alvarez, M. J., Honan, E., Yang, M., Chia, P. L., Mukhopadhyay, P., Kelly, S., Wu, R., Fenn, K., Trivedi, M. S., Accordino, M., Crew, K. D., Hershman, D. L., Maurer, M., … Silva, J. (2022). Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer. Nature Cancer, 4(2), 257–275. https://doi.org/10.1038/s43018-022-00489-5
Authors:
Tizita Z Zeleke
Qingfei Pan
Codruta Chiuzan
Maika Onishi
Yuxin Li
Haiyan Tan
Mariano J Alvarez
Erin Honan
Min Yang
Pei Ling Chia
Partha Mukhopadhyay
Sean Kelly
Ruby Wu
Kathleen Fenn
Meghna S Trivedi
Melissa Accordino
Katherine D Crew
Dawn L Hershman
Matthew Maurer
Simon Jones
Anthony High
Junmin Peng
Andrea Califano
Kevin Kalinsky
Jiyang Yu
Jose Silva
Affiliated Authors:
Mariano J Alvarez
Andrea Califano
Subjects:
Publication Type:
Article
Unique ID:
10.1038/s43018-022-00489-5
PMID:
Journal:
Publication Date:
Data Source:
PubMed

Record Created: